Trial Profile
Abatacept - Long-Term Real-Life Experience in Psoriatic Arthritis (PsA) in Germany: an Observational Study (ALTEA)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Jun 2022
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms ALTEA
- Sponsors Bristol-Myers Squibb
- 26 May 2022 Status changed from active, no longer recruiting to completed.
- 03 Sep 2021 Planned End Date changed from 31 Mar 2021 to 31 Mar 2022.
- 03 Sep 2021 Planned primary completion date changed from 30 Mar 2020 to 31 Mar 2022.